Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
Key Impact
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Background & Research
Mathieu Seynaeve, MD, is a psychiatrist and psychedelic clinical researcher at Beckley Psytech. According to conference and company materials, he serves as Senior Medical Director and Head of Psychotherapy, where he has helped design clinical studies of 5-MeO-DMT and related psychotherapeutic support models. He previously worked in the Psychoactive Trials Group at the Centre for Affective Disorders, IoPPN, on placebo-controlled psilocybin trials, and is pursuing a PhD on psychological mechanisms of psychedelic psychotherapy.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →